Get the Stockscreener App
1.7769
15.38%
0.2369
Pre-market:
1.79
0.0131
+0.74%
Sellas Life Sciences Group Inc stock is traded at $1.7769, with a volume of 9.87M.
It is up +15.38% in the last 24 hours and up +7.04% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$1.54
Open:
$1.54
24h Volume:
9.87M
Relative Volume:
2.78
Market Cap:
$253.11M
Revenue:
-
Net Income/Loss:
$-37.34M
P/E Ratio:
-1.3065
EPS:
-1.36
Net Cash Flow:
$-36.91M
1W Performance:
+21.71%
1M Performance:
+7.04%
6M Performance:
+11.06%
1Y Performance:
+60.08%
1-Day Range:
$1.518
$1.8399
1-Week Range:
$1.39
$1.8399
52-Week Range:
$0.772
$2.48
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Compare SLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.7769 | 219.36M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-18 | Initiated | Oppenheimer | Outperform |
| Apr-02-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
Sellas Life Sciences Progress Sparks Optimism in Market - StocksToTrade
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - The Malaysian Reserve
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - Benzinga
SELLAS Life Sciences Gains Momentum with Impressive Phase 2 Data and Financial Strength - timothysykes.com
How institutional buying supports SELLAS Life Sciences Group Inc. stockShare Buyback & High Accuracy Trade Alerts - Newser
How SELLAS Life Sciences Group Inc. (RXK3) stock compares with top peersQuarterly Profit Review & Stock Portfolio Risk Control - Newser
Is SELLAS Life Sciences Group Inc. (RXK3) stock cheap by valuation metrics2025 Investor Takeaways & Long-Term Safe Investment Plans - Newser
Is SELLAS Life Sciences Group Inc. (RXK3) stock a contrarian opportunityBreakout Watch & Weekly Chart Analysis and Guides - Newser
SELLAS Life Sciences Group Inc RXK3 Stock Analysis and ForecastStock Split Announcements & Technical + Fundamental = Smarter Investing - earlytimes.in
[EFFECT] SELLAS Life Sciences Group, Inc. SEC Filing - Stock Titan
SELLAS Advances AML Pipeline With GPS And SLS009 - RTTNews
Katherine Bach Kalin Acquires 63,400 Shares of SELLAS Life Sciences Group (NASDAQ:SLS) Stock - MarketBeat
Katherine Kalin Increases Stake in SELLAS Life Sciences Group Inc - GuruFocus
Kalin Katherine Bach buys SELLAS Life Sciences (SLS) shares By Investing.com - Investing.com Nigeria
Kalin Katherine Bach buys SELLAS Life Sciences (SLS) shares - Investing.com
[Form 4] SELLAS Life Sciences Group, Inc. Insider Trading Activity - Stock Titan
Analyzing SELLAS Life Sciences Group Inc. with risk reward ratio chartsWeekly Gains Report & Precise Swing Trade Alerts - newser.com
How SELLAS Life Sciences Group Inc. stock valuations compare to rivals2025 Macro Impact & Free Safe Capital Growth Stock Tips - newser.com
Does SELLAS Life Sciences Group Inc. show high probability of rebound - newser.com
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS) - MarketBeat
How risky is SELLAS Life Sciences Group Inc. stock nowPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
Can SELLAS Life Sciences Group Inc. (RXK3) stock hold up in economic slowdown2025 Earnings Impact & Short-Term Trading Opportunity Alerts - newser.com
SELLAS Life Sciences Group Inc. stock prediction for this weekWeekly Investment Recap & Weekly Breakout Stock Alerts - newser.com
Why millennials buy SELLAS Life Sciences Group Inc. (RXK3) stock2025 Growth vs Value & Daily Momentum Trading Reports - newser.com
SELLAS Life Sciences Group Inc. stock trend forecastWeekly Trade Analysis & Verified Trade Idea Suggestions - newser.com
Is SELLAS Life Sciences Group Inc. showing signs of accumulationWeekly Trend Report & Entry and Exit Point Strategies - newser.com
Is SELLAS Life Sciences Group Inc. reversing from oversold territory2025 Investor Takeaways & Free Fast Entry Momentum Trade Alerts - newser.com
Should you wait for a breakout in SELLAS Life Sciences Group Inc.Earnings Recap Report & Smart Money Movement Tracker - newser.com
Will SELLAS Life Sciences Group Inc. (RXK3) stock test record highs in 20252025 Dividend Review & Long-Term Growth Portfolio Plans - newser.com
Using economic indicators to assess SELLAS Life Sciences Group Inc. potentialPortfolio Profit Report & Safe Capital Growth Tips - newser.com
Does SELLAS Life Sciences Group Inc. fit your quant trading modelEarnings Risk Report & AI Enhanced Trading Alerts - newser.com
SELLAS Life Sciences Group Inc. stock outlook for YEARJuly 2025 Reactions & Consistent Return Strategy Ideas - newser.com
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):